Used in combination with pibrentasvir, it treats chronic hepatitis C virus (HCV) infection across all major genotypes. It is effective in both treatment-naive patients and those who have failed prior therapies. The combination works by inhibiting the NS3/4A protease, a key enzyme in HCV replication, thereby reducing viral load and achieving high rates of sustained virologic response. It is prescribed for adults and certain adolescents, including those with compensated liver disease, and has shown efficacy in patients with or without cirrhosis. Its once-daily dosing and pan-genotypic activity make it a preferred option in modern HCV treatment regimens.